Q32 Bio Raises $55M with $8.00 Shares to Fund Alopecia Areata Phase 2
QTTB•Q32 Bio raised $55 million by issuing 6.725 million common shares at $8.00 and 150,000 pre-funded warrants exercisable at $7.9999. Net proceeds will finance Phase 2 studies of bempikibart, its fully human anti-IL-7Rα antibody therapy for alopecia areata.
1. Private Placement Details
Q32 Bio completed an agreement to issue 6,725,000 common shares at $8.00 each and 150,000 pre-funded warrants exercisable at $7.9999 per warrant, raising approximately $55 million in gross proceeds. The transaction is set to close on May 28, 2026, subject to customary closing conditions.
2. Investor Participation
The financing was led by BVF Partners with additional participation from RA Capital Management, OrbiMed and Atlas Venture. Morgan Stanley served as lead placement agent while Oppenheimer & Co. acted as placement agent for the offering.
3. Use of Proceeds
Net proceeds will strengthen the company’s balance sheet and extend its operational runway. Funds are designated to support ongoing research, manufacturing scale-up and clinical costs for bempikibart’s Phase 2 program.
4. Clinical Development Plans
Bempikibart is a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function in T cell–mediated alopecia areata. The ongoing Phase 2 trial will assess safety, dosing and efficacy in moderate-to-severe patients, with topline results expected by late 2026.
